Guard Therapeutics International AB (publ)

Stockholm Stock Exchange GUARD.ST

Guard Therapeutics International AB (publ) Free Cash Flow for the year ending December 31, 2023: USD -11.45 M

Guard Therapeutics International AB (publ) Free Cash Flow is USD -11.45 M for the year ending December 31, 2023, a -17.42% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.
  • Guard Therapeutics International AB (publ) Free Cash Flow for the year ending December 31, 2022 was USD -9.75 M, a -14.18% change year over year.
  • Guard Therapeutics International AB (publ) Free Cash Flow for the year ending December 31, 2021 was USD -8.54 M, a -85.67% change year over year.
  • Guard Therapeutics International AB (publ) Free Cash Flow for the year ending December 31, 2020 was USD -4.60 M, a 28.27% change year over year.
  • Guard Therapeutics International AB (publ) Free Cash Flow for the year ending December 31, 2019 was USD -6.41 M, a 2.47% change year over year.
Key data
Date Free Cash Flow Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities
Market news
Loading...
Stockholm Stock Exchange: GUARD.ST

Guard Therapeutics International AB (publ)

CEO Mr. Tobias Larsson Agervald
IPO Date April 3, 2013
Location Sweden
Headquarters Nybrogatan 34, 2 tr
Employees 11
Sector Health Care
Industries
Description

Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.

Similar companies

BINV.ST

BioInvent International AB (publ)

USD 2.74

1.67%

ACE.ST

Ascelia Pharma AB (publ)

USD 0.25

-2.43%

ISOFOL.ST

Isofol Medical AB (publ)

USD 0.20

1.12%

IMMU.ST

Mendus AB (publ)

USD 0.71

-2.02%

StockViz Staff

January 15, 2025

Any question? Send us an email